Heras, M., Chesebro, J.H., Fuster, V., Penny, W.J., Grill, D.E., Bailey, K.R., Danielson, G.K., Orszulak, T.A., Pluth, J.R., Puga, F.J., Schaff, H.V. and Larsonkeller, J.J. (1995) High risk of Thromboemboli Early after Bioprosthetic Cardiac Valve Replacement. Journal of the American College of Cardiology, 25, 1111-1119.
http://dx.doi.org/10.1016/0735-1097(94)00563-6

has been cited by the following article:

• TITLE: Early Postoperative Anticoagulation by Enoxaparin after Mechanical Aortic Valve Replacement

  AUTHORS: Younes Moutakiallah, Mehdi Bamous, Roland Henaine, Jacques Robin, Jean François Obadia, Jean Ninet

  KEYWORDS: Early Anticoagulation, Mechanical Aortic Valve Replacement, Low Molecular Weight Heparin

  JOURNAL NAME: World Journal of Cardiovascular Surgery, Vol.4 No.7, July 14, 2014

  ABSTRACT: Background: The use of low molecular weight heparin for early anticoagulation after mechanical aortic valve replacement is still a matter of debate even more that the early postoperative phase is associated with maximum of thrombo-embolic and bleeding risks. The objective of this study is to verify the efficacy and the safety of low molecular weight heparin for the early anticoagulation after mechanical aortic valve replacement. Methods and Results: It is a prospective study conducted over 6 months and interested 40 consecutive patients (32 male and 8 female) with a mean age 53.83 ± 16.93 years (19-75 years) who underwent a mechanical aortic valve replacement and received enoxaparin as bridging therapy between continuous unfractionated heparin and fully effective vitamin K antagonist therapy. There was no in-hospital death and no in-hospital thromboembolic events. We report 2 major bleeding events (5%). Conclusion: The use of low molecular weight heparin should be an alternative to explore for early anticoagulation after valve heart surgery and the results of our study must be verified by large randomized studies before drawing any hasty conclusions.